Ornithine aspartate and vitamin-E combination has beneficial effects on cardiovascular risk factors in an animal model of nonalcoholic fatty liver disease in rats
dc.contributor.author | Freitas, Laura Bainy Rodrigues de | pt_BR |
dc.contributor.author | Longo, Larisse | pt_BR |
dc.contributor.author | Chiela, Eduardo Cremonese Filippi | pt_BR |
dc.contributor.author | Souza, Valessa Emanoele Gabriel de | pt_BR |
dc.contributor.author | Behrens, Luiza Marques Prates | pt_BR |
dc.contributor.author | Pereira, Matheus Henrique Mariano | pt_BR |
dc.contributor.author | Leonhard, Luiza Cecília | pt_BR |
dc.contributor.author | Zanettini, Giulianna | pt_BR |
dc.contributor.author | Pinzon, Carlos Eduardo | pt_BR |
dc.contributor.author | Luchese, Eduardo Dal-Lomo | pt_BR |
dc.contributor.author | Lima, Guilherme Jorge Semmelmann Pereira | pt_BR |
dc.contributor.author | Cerski, Carlos Thadeu Schmidt | pt_BR |
dc.contributor.author | Cruz, Carolina Uribe | pt_BR |
dc.contributor.author | Álvares-da-Silva, Mário Reis | pt_BR |
dc.date.accessioned | 2023-11-18T03:26:56Z | pt_BR |
dc.date.issued | 2022 | pt_BR |
dc.identifier.issn | 2218-273X | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/267285 | pt_BR |
dc.description.abstract | Cardiovascular (CV) disease is the main cause of death in nonalcoholic fatty liver disease (NAFLD), a clinical condition without any approved pharmacological therapy. Thus, we investigated the effects of ornithine aspartate (LOLA) and/or Vitamin E (VitE) on CV parameters in a steatohepatitis experimental model. Adult Sprague Dawley rats were randomly assigned (10 animals each) and treated from 16 to 28 weeks with gavage as follows: controls (standard diet plus distilled water (DW)), NAFLD (high-fat choline-deficient diet (HFCD) plus DW), NAFLD+LOLA (HFCD plus LOLA (200 mg/kg/day)), NAFLD+VitE (HFCD plus VitE (150 mg twice a week)) or NAFLD+LOLA+VitE in the same doses. Atherogenic ratios were higher in NAFLD when compared with NAFLD+LOLA+VitE and controls (p < 0.05). Serum concentration of IL-1β, IL-6, TNF-α, MCP-1, e-selectin, ICAM-1, and PAI-1 were not different in intervention groups and controls (p > 0.05). NAFLD+LOLA decreased miR-122, miR-33a, and miR-186 (p < 0.05, for all) in relation to NAFLD. NAFLD+LOLA+VitE decreased miR-122, miR-33a and miR-186, and increased miR-126 (p < 0.05, for all) in comparison to NAFLD and NAFLD+VitE. NAFLD+LOLA and NAFLD+LOLA+VitE prevented liver collagen deposition (p = 0.006) in comparison to NAFLD. Normal cardiac fibers (size and shape) were lower in NAFLD in relation to the others; and the inverse was reported for the percentage of regular hypertrophic cardiomyocytes. NAFLD+LOLA+VitE promoted a significant improvement in atherogenic dyslipidemia, liver fibrosis, and paracrine signaling of lipid metabolism and endothelial dysfunction. This association should be further explored in the treatment of NAFLD-associated CV risk factors. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Biomolecules. Basel. Vol. 12, no. 12 (2022), artigo 1773, 18 p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Animal model | en |
dc.subject | Modelos animais de doenças | pt_BR |
dc.subject | Doenças cardiovasculares | pt_BR |
dc.subject | Cardiovascular risk | en |
dc.subject | Nonalcoholic fatty liver disease | en |
dc.subject | Fatores de risco | pt_BR |
dc.subject | Vitamina E | pt_BR |
dc.subject | Ornithine aspartate | en |
dc.subject | Hepatopatia gordurosa não alcoólica | pt_BR |
dc.subject | Steatohepatitis | en |
dc.subject | Ornitina | pt_BR |
dc.subject | Vitamin E | en |
dc.title | Ornithine aspartate and vitamin-E combination has beneficial effects on cardiovascular risk factors in an animal model of nonalcoholic fatty liver disease in rats | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001186960 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (39859)Ciências Biológicas (3116)
-
Artigos de Periódicos (39859)Ciências da Saúde (10666)